120 related articles for article (PubMed ID: 15010837)
1. HER2/neu-derived peptides recognized by both cellular and humoral immune systems in HLA-A2+ cancer patients.
Ishihara Y; Harada M; Azuma K; Tamura M; Shomura H; Fujii T; Itoh K; Shichijo S
Int J Oncol; 2004 Apr; 24(4):967-75. PubMed ID: 15010837
[TBL] [Abstract][Full Text] [Related]
2. Identification of HER2/neu-derived peptide epitopes recognized by gastric cancer-specific cytotoxic T lymphocytes.
Kono K; Rongcun Y; Charo J; Ichihara F; Celis E; Sette A; Appella E; Sekikawa T; Matsumoto Y; Kiessling R
Int J Cancer; 1998 Oct; 78(2):202-8. PubMed ID: 9754653
[TBL] [Abstract][Full Text] [Related]
3. The HER2/neu-derived peptide p654-662 is a tumor-associated antigen in human pancreatic cancer recognized by cytotoxic T lymphocytes.
Peiper M; Goedegebuure PS; Linehan DC; Ganguly E; Douville CC; Eberlein TJ
Eur J Immunol; 1997 May; 27(5):1115-23. PubMed ID: 9174600
[TBL] [Abstract][Full Text] [Related]
4. Natural CD8+ T-cell responses against MHC class I epitopes of the HER-2/ neu oncoprotein in patients with epithelial tumors.
Sotiropoulou PA; Perez SA; Voelter V; Echner H; Missitzis I; Tsavaris NB; Papamichail M; Baxevanis CN
Cancer Immunol Immunother; 2003 Dec; 52(12):771-9. PubMed ID: 13680193
[TBL] [Abstract][Full Text] [Related]
5. Modification of the HER2/NEU-derived tumor antigen GP2 improves induction of GP2-reactive cytotoxic T lymphocytes.
Tanaka Y; Amos KD; Joo HG; Eberlein TJ; Goedegebuure PS
Int J Cancer; 2001 Nov; 94(4):540-4. PubMed ID: 11745441
[TBL] [Abstract][Full Text] [Related]
6. Identification of new prostate stem cell antigen-derived peptides immunogenic in HLA-A2(+) patients with hormone-refractory prostate cancer.
Matsueda S; Kobayashi K; Nonaka Y; Noguchi M; Itoh K; Harada M
Cancer Immunol Immunother; 2004 Jun; 53(6):479-89. PubMed ID: 14634796
[TBL] [Abstract][Full Text] [Related]
7. Her-2/neu-derived peptides are tumor-associated antigens expressed by human renal cell and colon carcinoma lines and are recognized by in vitro induced specific cytotoxic T lymphocytes.
Brossart P; Stuhler G; Flad T; Stevanovic S; Rammensee HG; Kanz L; Brugger W
Cancer Res; 1998 Feb; 58(4):732-6. PubMed ID: 9485028
[TBL] [Abstract][Full Text] [Related]
8. Identification of HER2/ neu-derived peptides capable of inducing both cellular and humoral immune responses in HLA-A24 positive breast cancer patients.
Azuma K; Shichijo S; Shomura H; Matsueda S; Fujii T; Itoh K
Breast Cancer Res Treat; 2004 Jul; 86(1):19-29. PubMed ID: 15218358
[TBL] [Abstract][Full Text] [Related]
9. Exosomal pMHC-I complex targets T cell-based vaccine to directly stimulate CTL responses leading to antitumor immunity in transgenic FVBneuN and HLA-A2/HER2 mice and eradicating trastuzumab-resistant tumor in athymic nude mice.
Wang L; Xie Y; Ahmed KA; Ahmed S; Sami A; Chibbar R; Xu Q; Kane SE; Hao S; Mulligan SJ; Xiang J
Breast Cancer Res Treat; 2013 Jul; 140(2):273-84. PubMed ID: 23881522
[TBL] [Abstract][Full Text] [Related]
10. HER-2/neu is expressed in human renal cell carcinoma at heterogeneous levels independently of tumor grading and staging and can be recognized by HLA-A2.1-restricted cytotoxic T lymphocytes.
Seliger B; Rongcun Y; Atkins D; Hammers S; Huber C; Störkel S; Kiessling R
Int J Cancer; 2000 Aug; 87(3):349-59. PubMed ID: 10897039
[TBL] [Abstract][Full Text] [Related]
11. HER2/neu-derived peptides are shared antigens among human non-small cell lung cancer and ovarian cancer.
Yoshino I; Goedegebuure PS; Peoples GE; Parikh AS; DiMaio JM; Lyerly HK; Gazdar AF; Eberlein TJ
Cancer Res; 1994 Jul; 54(13):3387-90. PubMed ID: 7912166
[TBL] [Abstract][Full Text] [Related]
12. A Therapeutic Her2/neu Vaccine Targeting Dendritic Cells Preferentially Inhibits the Growth of Low Her2/neu-Expressing Tumor in HLA-A2 Transgenic Mice.
Tran T; Diniz MO; Dransart E; Gey A; Merillon N; Lone YC; Godefroy S; Sibley C; Ferreira LC; Medioni J; Oudard S; Johannes L; Tartour E
Clin Cancer Res; 2016 Aug; 22(16):4133-44. PubMed ID: 27006496
[TBL] [Abstract][Full Text] [Related]
13. Generation of peptide-specific cytotoxic T lymphocytes using allogeneic dendritic cells capable of lysing human pancreatic cancer cells.
Peiper M; Goedegebuure PS; Eberlein TJ
Surgery; 1997 Aug; 122(2):235-41; discussion 241-2. PubMed ID: 9288128
[TBL] [Abstract][Full Text] [Related]
14. Identification of new HER2/neu-derived peptide epitopes that can elicit specific CTL against autologous and allogeneic carcinomas and melanomas.
Rongcun Y; Salazar-Onfray F; Charo J; Malmberg KJ; Evrin K; Maes H; Kono K; Hising C; Petersson M; Larsson O; Lan L; Appella E; Sette A; Celis E; Kiessling R
J Immunol; 1999 Jul; 163(2):1037-44. PubMed ID: 10395702
[TBL] [Abstract][Full Text] [Related]
15. Heterologous human/rat HER2-specific exosome-targeted T cell vaccine stimulates potent humoral and CTL responses leading to enhanced circumvention of HER2 tolerance in double transgenic HLA-A2/HER2 mice.
Xie Y; Wu J; Xu A; Ahmeqd S; Sami A; Chibbar R; Freywald A; Zheng C; Xiang J
Vaccine; 2018 Mar; 36(11):1414-1422. PubMed ID: 29415817
[TBL] [Abstract][Full Text] [Related]
16. Tumor-specific and HLA-A2-restricted cytolysis by tumor-associated lymphocytes in human metastatic breast cancer.
Linehan DC; Goedegebuure PS; Peoples GE; Rogers SO; Eberlein TJ
J Immunol; 1995 Nov; 155(9):4486-91. PubMed ID: 7594611
[TBL] [Abstract][Full Text] [Related]
17. Association of HER2/neu expression with sensitivity to tumor-specific CTL in human ovarian cancer.
Yoshino I; Peoples GE; Goedegebuure PS; Maziarz R; Eberlein TJ
J Immunol; 1994 Mar; 152(5):2393-400. PubMed ID: 8133050
[TBL] [Abstract][Full Text] [Related]
18. Pancreatic cancer associated ascites-derived CTL recognize a nine-amino-acid peptide GP2 derived from HER2/neu.
Peiper M; Goedegebuure PS; Izbicki JR; Eberlein TJ
Anticancer Res; 1999; 19(4A):2471-5. PubMed ID: 10470176
[TBL] [Abstract][Full Text] [Related]
19. Direct measurement of peptide-specific CD8+ T cells using HLA-A2:Ig dimer for monitoring the in vivo immune response to a HER2/neu vaccine in breast and prostate cancer patients.
Woll MM; Fisher CM; Ryan GB; Gurney JM; Storrer CE; Ioannides CG; Shriver CD; Moul JW; McLeod DG; Ponniah S; Peoples GE
J Clin Immunol; 2004 Jul; 24(4):449-61. PubMed ID: 15163902
[TBL] [Abstract][Full Text] [Related]
20. TCR V beta 3+ and V beta 6+ CTL recognize tumor-associated antigens related to HER2/neu expression in HLA-A2+ ovarian cancers.
Peoples GE; Yoshino I; Douville CC; Andrews JV; Goedegebuure PS; Eberlein TJ
J Immunol; 1994 May; 152(10):4993-9. PubMed ID: 7909829
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
